Clinical trials regarding TP-0903 as a monotherapy include patients with CLL, refractory solid tumors and FLT3 mutated AML (NCT03572634, NCT02729298 and NCT04518345). The gene discussed is FLT3; the disease is acute myeloid leukemia.